An open-label, multicenter, phase 2 trial evaluated the antitumor activity of a combination of ICIs and EGFR inhibitor for R/M HNSCC and the results showed promising clinical activity with ORR of 45%22. Here, EGFR is linked to head and neck squamous cell carcinoma.